AnaptysBio Inc. (ANAB)
NASDAQ: ANABHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
ANAB stock chart
Technical analysisKey statistics
All statistics- Market cap
- $1.39B
- P/E (TTM)
- 7.15
- Forward P/E
- 8.66
- EPS (TTM)
- $6.52
- Dividend yield
- None
- 52-week range
- 26.01 – 72.36
- Day range
- 46.05 – 47.66
- Volume / Avg
- 432.44K / 496.92K
- Beta
- —
- Shares outstanding
- 29.73M
52-week range
ANAB stock today
On Nov 20, ANAB ended the session at $46.63, shedding $0.77 (1.62%), versus the S&P 500's 3.70% decline. At this level, ANAB sits in the middle of its 52-week range of $26.01 to $72.36: 35.6% below the high, set on May 5, 2026 and 79.3% above the low. ANAB is up 44.3% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 76.6%.
At 7.2x trailing earnings, AnaptysBio trades below the peer-group median of 9.4x. Its forward P/E of 8.7x is higher than the trailing multiple, which means analysts expect earnings to decline over the next year.
Summary generated from market data by MetaCap's automated system. Methodology
About AnaptysBio
Company profileAnaptysBio, Inc. discovers and out-licenses therapeutic bodies in the United States. The company manages financial collaborations for Jemperli, a PD-1 antagonist for various solid tumor indications; and Quimilza, an IL-36R antagonist mAb, which has completed two registration-enabling global Phase 3 trials, and GEMINI-1 and GEMINI-2, evaluating the safety and efficacy of Quimilza in patients with generalized pustular psoriasis.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Daniel R. Faga
- Headquarters
- San Diego, CA
- IPO year
- 2017
- Website
- anaptysbio.com
Financial highlights
Full financialsIn fiscal 2025, AnaptysBio generated $234.6 million in revenue, up 157.0% from fiscal 2024, its 3rd consecutive year of revenue growth. AnaptysBio reported a net loss of $13.2 million, compared with a loss of $145.2 million a year earlier. Operating margin was 96.7%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $234.60M | $91.28M | $17.16M | $10.29M | $63.17M |
| Growth | +157.01% | +432.03% | +66.78% | -83.72% | -15.77% |
| Net income | $-13.23M | $-145.23M | $-163.62M | $-128.72M | $-57.80M |
| EPS (diluted) | $-0.44 | $-4.92 | $-6.08 | $-4.57 | $-2.11 |
Analyst forecast
ForecastConsensus (8 analysts)
strong_buy
Avg. price target
$87.25+87.11%
- Strong buy 3
- Buy 5
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 12, 2026
- EPS actual vs est.
- $0.11 vs $0.41
- Surprise
- -73.17%
ANAB news
All ANAB news- 3 Stocks With Superb Earnings Acceleration to Buy Before 2027NasdaqCEVA, ENSG, ANAB
- AnaptysBio, Inc. Reports Collaboration Revenue of $30.3 million for the Three Months Ended September 30, 2026Nasdaq
- AnaptysBio GAAP EPS of $0.11 misses by $0.28, revenue of $30.27M misses by $3.19MSeeking Alpha
- Anaptys Reports Fiscal First Quarter 2027 Financial Results and Provides Business UpdateGlobeNewswire
- Anaptys Announces Participation in Upcoming Investor ConferencesGlobeNewswire
- AnaptysBio, Inc. (ANAB) Expected to Beat Earnings Estimates: Should You Buy?NasdaqANAB, BMY
- AnaptysBio quickly drops amid hearing on GSK/Tesaro contract breachSeeking Alpha
- CytoDyn Appoints Robert E. Hoffman As CEO; Lalezari To Focus On ResearchNasdaqANAB, HRTX, SUN
AnaptysBio peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| NRIXNurix Therapeutics Inc. | 12.85 | -5.55% | $1.40B | vs ANAB |
| ADRXADARx Pharmaceuticals Inc. | 12.79 | -9.68% | $1.42B | vs ANAB |
| TYRATyra Biosciences Inc. | 20.12 | +1.98% | $1.39B | vs ANAB |
| SRPTSarepta Therapeutics Inc. | 13.33 | -5.93% | $1.43B | vs ANAB |
| KLRAKailera Therapeutics Inc. | 11.02 | -4.84% | $1.43B | vs ANAB |
| DMRADamora Therapeutics Inc. | 23.22 | -4.44% | $1.44B | vs ANAB |
| RAPPRapport Therapeutics Inc. | 23.16 | -1.82% | $1.37B | vs ANAB |
| QUREuniQure N.V. | 19.35 | -4.35% | $1.36B | vs ANAB |
Indexes, lists and sector
AnaptysBio stock FAQ
What is AnaptysBio's stock price today?
ANAB last traded at $46.63 as of Nov 20, 4:00 PM EST, down 1.62% on the day. Prices are delayed at least 15 minutes.
Does AnaptysBio pay a dividend?
No. AnaptysBio does not currently pay a regular cash dividend.
What is ANAB's P/E ratio?
ANAB trades at a trailing P/E ratio of 7.15 and a forward P/E of 8.66, compared with a median of 9.4 for its closest peers.
Who is AnaptysBio's CEO?
Mr. Daniel R. Faga is the chief executive officer of AnaptysBio Inc..
Has ANAB ever split its stock?
Yes. The most recent ANAB stock split was a 15-for-10 split on Apr 20, 2026.
What is the ANAB 52-week high?
The 52-week high for ANAB is $72.36 and the 52-week low is $26.01. The stock is currently 35.6% below its high.